secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2023-06-09T23:59:59+00:00
Accession:  0001193125-23-164542
Event type: other
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Finch Therapeutics shareholders approve 1-for-30 reverse stock split; elect two directors
--------------------------------------------------------------------------------

- Reverse stock split at 1-for-30 ratio approved by 40,212,819 votes for, 717,495 against.
- Common stock to begin trading on post-split basis on June 12, 2023 under new CUSIP 31773D200.
- Susan Graf and Chris Shumway elected as Class II directors through 2026; Graf 26,097,717 votes for, Shumway 24,013,503.
- Annual meeting had 40,934,688 shares present (~85.02% of outstanding).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000119312523164542/0001193125-23-164542-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000119312523164542/d620811d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-164542

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer